chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Peripheral swelling, Vaccination site warmth
Clinical narrative: Knot in the left arm about the size of a golf ball; pain in arm; Warm to touch; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 12-May-2021 and was forwarded to Moderna on 17-May-2021.    This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (Knot in the left arm about the size of a golf ball), PAIN IN EXTREMITY (pain in arm) and VACCINATION SITE WARMTH (Warm to touch) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 07-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-May-2021, the patient experienced PERIPHERAL SWELLING (Knot in the left arm about the size of a golf ball), PAIN IN EXTREMITY (pain in arm) and VACCINATION SITE WARMTH (Warm to touch). At the time of the report, PERIPHERAL SWELLING (Knot in the left arm about the size of a golf ball), PAIN IN EXTREMITY (pain in arm) and VACCINATION SITE WARMTH (Warm to touch) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Reportedly, the patient was taking some other unspecified medications. Treatment details were not provided.   This case was linked to US-MODERNATX, INC.-MOD-2021-138301 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-138301:crosslinked
Age: 57.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature fluctuation, Diarrhoea, Hot flush, Loss of personal independence in daily activities, Myalgia
Clinical narrative: "He had heat flashes"; "He was cold and then hot"; had Diarrhea"; "We just laid around for two days doing nothing"; "He felt achy, like achy bones"; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 17-May-2021 and was forwarded to Moderna on 17-May-2021.    This spontaneous case was reported by a consumer and describes the occurrence of HOT FLUSH ("He had heat flashes"), BODY TEMPERATURE FLUCTUATION ("He was cold and then hot"), DIARRHOEA (had Diarrhea"), LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES ("We just laid around for two days doing nothing") and MYALGIA ("He felt achy, like achy bones") in a 57-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031B21A and 003C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 31-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 31-Mar-2021, the patient experienced HOT FLUSH ("He had heat flashes"), BODY TEMPERATURE FLUCTUATION ("He was cold and then hot"), DIARRHOEA (had Diarrhea"), LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES ("We just laid around for two days doing nothing") and MYALGIA ("He felt achy, like achy bones"). On 17-May-2021, HOT FLUSH ("He had heat flashes"), BODY TEMPERATURE FLUCTUATION ("He was cold and then hot"), DIARRHOEA (had Diarrhea"), LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES ("We just laid around for two days doing nothing") and MYALGIA ("He felt achy, like achy bones") had resolved.      No concomitant medications were provided Treatment for the events were not provided   This case was linked to US-MODERNATX, INC.-MOD-2021-067576 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-067576:CROSS LINKED WITH WIFE CASE
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: Amnesia, Body temperature, Eye opacity, Fatigue, Lymphadenopathy
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Second dose not administered within 35 days), ORAL HERPES (developed herps libilails HSA# 1), SOMNOLENCE (ll the time are tired and sleepy), POLLAKIURIA (frequent urination 6 times in less than an hour) and SKIN PAPILLOMA (eye problem white foggy spots and wart like in the top inside right lid.) in a 42-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 032L20A and 004d21a) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.  Concurrent medical conditions included Hypothyroidism. On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Jul-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 2 dosage form. On 12-Feb-2021, the patient experienced VACCINATION SITE PAIN (Slight tenderness at the injection site). On 11-Jul-2021, the patient experienced ORAL HERPES (developed herps libilails HSA# 1), SOMNOLENCE (ll the time are tired and sleepy), POLLAKIURIA (frequent urination 6 times in less than an hour), SKIN PAPILLOMA (eye problem white foggy spots and wart like in the top inside right lid.), EYE OPACITY (eye problem white foggy spots and wart like in the top inside right lid.), AMNESIA (memory loss cant remmber the things easily), LYMPHADENOPATHY (Left arm axillariy lymphnodes swelling) and FATIGUE (ll the time are tired and sleepy). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Second dose not administered within 35 days). On 14-Feb-2021, VACCINATION SITE PAIN (Slight tenderness at the injection site) had resolved. At the time of the report, PRODUCT DOSE OMISSION ISSUE (Second dose not administered within 35 days) had resolved and ORAL HERPES (developed herps libilails HSA# 1), SOMNOLENCE (ll the time are tired and sleepy), POLLAKIURIA (frequent urination 6 times in less than an hour), SKIN PAPILLOMA (eye problem white foggy spots and wart like in the top inside right lid.), EYE OPACITY (eye problem white foggy spots and wart like in the top inside right lid.), AMNESIA (memory loss cant remmber the things easily), LYMPHADENOPATHY (Left arm axillariy lymphnodes swelling) and FATIGUE (ll the time are tired and sleepy) outcome was unknown. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: above 38 (High) High. Patient states that he was not able to work properly.  No relevant concomitant medication was reported. Treatment information was not provided. Most recent FOLLOW-UP information incorporated above includes: On 16-Jul-2021: Follow-up information received, contains significant information. Other relevant  History, Dose-2 details,Vaccine Facility type, Action taken ,dechallenge, Events were added
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: Oral herpes, Pollakiuria, Product dose omission issue, Skin papilloma, Somnolence
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Second dose not administered within 35 days), ORAL HERPES (developed herps libilails HSA# 1), SOMNOLENCE (ll the time are tired and sleepy), POLLAKIURIA (frequent urination 6 times in less than an hour) and SKIN PAPILLOMA (eye problem white foggy spots and wart like in the top inside right lid.) in a 42-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 032L20A and 004d21a) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.  Concurrent medical conditions included Hypothyroidism. On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Jul-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 2 dosage form. On 12-Feb-2021, the patient experienced VACCINATION SITE PAIN (Slight tenderness at the injection site). On 11-Jul-2021, the patient experienced ORAL HERPES (developed herps libilails HSA# 1), SOMNOLENCE (ll the time are tired and sleepy), POLLAKIURIA (frequent urination 6 times in less than an hour), SKIN PAPILLOMA (eye problem white foggy spots and wart like in the top inside right lid.), EYE OPACITY (eye problem white foggy spots and wart like in the top inside right lid.), AMNESIA (memory loss cant remmber the things easily), LYMPHADENOPATHY (Left arm axillariy lymphnodes swelling) and FATIGUE (ll the time are tired and sleepy). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Second dose not administered within 35 days). On 14-Feb-2021, VACCINATION SITE PAIN (Slight tenderness at the injection site) had resolved. At the time of the report, PRODUCT DOSE OMISSION ISSUE (Second dose not administered within 35 days) had resolved and ORAL HERPES (developed herps libilails HSA# 1), SOMNOLENCE (ll the time are tired and sleepy), POLLAKIURIA (frequent urination 6 times in less than an hour), SKIN PAPILLOMA (eye problem white foggy spots and wart like in the top inside right lid.), EYE OPACITY (eye problem white foggy spots and wart like in the top inside right lid.), AMNESIA (memory loss cant remmber the things easily), LYMPHADENOPATHY (Left arm axillariy lymphnodes swelling) and FATIGUE (ll the time are tired and sleepy) outcome was unknown. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: above 38 (High) High. Patient states that he was not able to work properly.  No relevant concomitant medication was reported. Treatment information was not provided. Most recent FOLLOW-UP information incorporated above includes: On 16-Jul-2021: Follow-up information received, contains significant information. Other relevant  History, Dose-2 details,Vaccine Facility type, Action taken ,dechallenge, Events were added
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Second dose not administered within 35 days), ORAL HERPES (developed herps libilails HSA# 1), SOMNOLENCE (ll the time are tired and sleepy), POLLAKIURIA (frequent urination 6 times in less than an hour) and SKIN PAPILLOMA (eye problem white foggy spots and wart like in the top inside right lid.) in a 42-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 032L20A and 004d21a) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.  Concurrent medical conditions included Hypothyroidism. On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Jul-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 2 dosage form. On 12-Feb-2021, the patient experienced VACCINATION SITE PAIN (Slight tenderness at the injection site). On 11-Jul-2021, the patient experienced ORAL HERPES (developed herps libilails HSA# 1), SOMNOLENCE (ll the time are tired and sleepy), POLLAKIURIA (frequent urination 6 times in less than an hour), SKIN PAPILLOMA (eye problem white foggy spots and wart like in the top inside right lid.), EYE OPACITY (eye problem white foggy spots and wart like in the top inside right lid.), AMNESIA (memory loss cant remmber the things easily), LYMPHADENOPATHY (Left arm axillariy lymphnodes swelling) and FATIGUE (ll the time are tired and sleepy). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Second dose not administered within 35 days). On 14-Feb-2021, VACCINATION SITE PAIN (Slight tenderness at the injection site) had resolved. At the time of the report, PRODUCT DOSE OMISSION ISSUE (Second dose not administered within 35 days) had resolved and ORAL HERPES (developed herps libilails HSA# 1), SOMNOLENCE (ll the time are tired and sleepy), POLLAKIURIA (frequent urination 6 times in less than an hour), SKIN PAPILLOMA (eye problem white foggy spots and wart like in the top inside right lid.), EYE OPACITY (eye problem white foggy spots and wart like in the top inside right lid.), AMNESIA (memory loss cant remmber the things easily), LYMPHADENOPATHY (Left arm axillariy lymphnodes swelling) and FATIGUE (ll the time are tired and sleepy) outcome was unknown. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: above 38 (High) High. Patient states that he was not able to work properly.  No relevant concomitant medication was reported. Treatment information was not provided. Most recent FOLLOW-UP information incorporated above includes: On 16-Jul-2021: Follow-up information received, contains significant information. Other relevant  History, Dose-2 details,Vaccine Facility type, Action taken ,dechallenge, Events were added
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site pain
Clinical narrative: Redness at the site of injection; Soreness at the site of injection; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE ERYTHEMA (Redness at the site of injection) and VACCINATION SITE PAIN (Soreness at the site of injection) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. No Medical History information was reported.    On 14-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-May-2021, the patient experienced VACCINATION SITE ERYTHEMA (Redness at the site of injection) and VACCINATION SITE PAIN (Soreness at the site of injection). At the time of the report, VACCINATION SITE ERYTHEMA (Redness at the site of injection) and VACCINATION SITE PAIN (Soreness at the site of injection) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medication information provided.  No relevant treatment medication information provided.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Gait disturbance, Headache, Heart rate increased
Clinical narrative: Headache; heart rate increased; walking difficulty; Palpitations; Chills; Nausea; Fatigue; Fever; myalgia; This spontaneous case was reported by a consumer and describes the occurrence of HEART RATE INCREASED (heart rate increased), GAIT DISTURBANCE (walking difficulty), PALPITATIONS (Palpitations), CHILLS (Chills) and NAUSEA (Nausea) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 040B21A and 040B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included OMEPRAZOLE for Gastric disorder, LEVOTHYROXINE for Hashimoto's disease.   On 15-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-May-2021, the patient experienced HEART RATE INCREASED (heart rate increased), GAIT DISTURBANCE (walking difficulty), PALPITATIONS (Palpitations), CHILLS (Chills), NAUSEA (Nausea), FATIGUE (Fatigue), PYREXIA (Fever) and MYALGIA (myalgia). On 16-May-2021, the patient experienced HEADACHE (Headache). On 16-May-2021, HEART RATE INCREASED (heart rate increased), GAIT DISTURBANCE (walking difficulty), PALPITATIONS (Palpitations), CHILLS (Chills), NAUSEA (Nausea), FATIGUE (Fatigue), PYREXIA (Fever) and MYALGIA (myalgia) had resolved. At the time of the report, HEADACHE (Headache) had not resolved.            No Conmeds and treatment medications was reported .  The action taken with mRNA-1273 was not applicable .
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Nausea, Palpitations, Pyrexia
Clinical narrative: Headache; heart rate increased; walking difficulty; Palpitations; Chills; Nausea; Fatigue; Fever; myalgia; This spontaneous case was reported by a consumer and describes the occurrence of HEART RATE INCREASED (heart rate increased), GAIT DISTURBANCE (walking difficulty), PALPITATIONS (Palpitations), CHILLS (Chills) and NAUSEA (Nausea) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 040B21A and 040B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included OMEPRAZOLE for Gastric disorder, LEVOTHYROXINE for Hashimoto's disease.   On 15-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-May-2021, the patient experienced HEART RATE INCREASED (heart rate increased), GAIT DISTURBANCE (walking difficulty), PALPITATIONS (Palpitations), CHILLS (Chills), NAUSEA (Nausea), FATIGUE (Fatigue), PYREXIA (Fever) and MYALGIA (myalgia). On 16-May-2021, the patient experienced HEADACHE (Headache). On 16-May-2021, HEART RATE INCREASED (heart rate increased), GAIT DISTURBANCE (walking difficulty), PALPITATIONS (Palpitations), CHILLS (Chills), NAUSEA (Nausea), FATIGUE (Fatigue), PYREXIA (Fever) and MYALGIA (myalgia) had resolved. At the time of the report, HEADACHE (Headache) had not resolved.            No Conmeds and treatment medications was reported .  The action taken with mRNA-1273 was not applicable .
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site rash
Clinical narrative: Rash on the injection site; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE RASH (Rash on the injection site) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027B21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included LISINOPRIL and ESTROGEN NOS;PROGESTERONE for an unknown indication.    On 29-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Apr-2021, the patient experienced VACCINATION SITE RASH (Rash on the injection site). The patient was treated with BETAMETHASONE DIPROPIONATE, CLOTRIMAZOLE (CLOTRIMAZOLE/BETAMETHASONE DIPROPIONATE) for Symptomatic treatment, at an unspecified dose and frequency. At the time of the report, VACCINATION SITE RASH (Rash on the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Doctor presumed the rash to be either wing worm or dermatitis and did not know whether the rash was due to the vaccine.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Hyperhidrosis, Hypersensitivity, Insomnia, Paraesthesia
Clinical narrative: Feels like she is having an allergic reaction on face, arms and hands after 1st dose; Pin pricking and needling after 1st dose; Sweats after the 1st dose; Can barely sleep after the 1st dose; Chills after the 1st dose; This spontaneous case was reported by a consumer and describes the occurrence of HYPERSENSITIVITY (Feels like she is having an allergic reaction on face, arms and hands after 1st dose), PARAESTHESIA (Pin pricking and needling after 1st dose), HYPERHIDROSIS (Sweats after the 1st dose), INSOMNIA (Can barely sleep after the 1st dose) and CHILLS (Chills after the 1st dose) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history reported by the reporter.  Concomitant products included ACETYLSALICYLIC ACID (ASPIRIN LOW) for an unknown indication.    On 22-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HYPERSENSITIVITY (Feels like she is having an allergic reaction on face, arms and hands after 1st dose), PARAESTHESIA (Pin pricking and needling after 1st dose), HYPERHIDROSIS (Sweats after the 1st dose), INSOMNIA (Can barely sleep after the 1st dose) and CHILLS (Chills after the 1st dose). At the time of the report, HYPERSENSITIVITY (Feels like she is having an allergic reaction on face, arms and hands after 1st dose), PARAESTHESIA (Pin pricking and needling after 1st dose), HYPERHIDROSIS (Sweats after the 1st dose), INSOMNIA (Can barely sleep after the 1st dose) and CHILLS (Chills after the 1st dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment information was provided.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Blood pressure measurement, Dizziness, Hyperhidrosis, Hypersensitivity
Clinical narrative: severe allergic reaction; felt very weak\weakness; very dizzy; sweated; the vein in her leg felt strange and swollen, under her groin; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (very dizzy), HYPERHIDROSIS (sweated), VASODILATATION (the vein in her leg felt strange and swollen, under her groin), ASTHENIA (felt very weak\weakness) and HYPERSENSITIVITY (severe allergic reaction) in a 43-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 043B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-Apr-2021, the patient experienced DIZZINESS (very dizzy), HYPERHIDROSIS (sweated) and VASODILATATION (the vein in her leg felt strange and swollen, under her groin). On 29-Apr-2021, the patient experienced ASTHENIA (felt very weak\weakness). On an unknown date, the patient experienced HYPERSENSITIVITY (severe allergic reaction). On 14-Apr-2021, DIZZINESS (very dizzy), HYPERHIDROSIS (sweated) and VASODILATATION (the vein in her leg felt strange and swollen, under her groin) had resolved. On 30-Apr-2021, ASTHENIA (felt very weak\weakness) had resolved. At the time of the report, HYPERSENSITIVITY (severe allergic reaction) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 14-Apr-2021, Blood pressure measurement: 70/40 decreased. On 29-Apr-2021, Oxygen saturation decreased: 90 oxygen was low, reaching 90.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication information was provided. The patient indicates that she does not take medications. Treatment medications provided by the reporter included apple juice and rest
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Oxygen saturation, Vasodilatation
Clinical narrative: severe allergic reaction; felt very weak\weakness; very dizzy; sweated; the vein in her leg felt strange and swollen, under her groin; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (very dizzy), HYPERHIDROSIS (sweated), VASODILATATION (the vein in her leg felt strange and swollen, under her groin), ASTHENIA (felt very weak\weakness) and HYPERSENSITIVITY (severe allergic reaction) in a 43-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 043B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-Apr-2021, the patient experienced DIZZINESS (very dizzy), HYPERHIDROSIS (sweated) and VASODILATATION (the vein in her leg felt strange and swollen, under her groin). On 29-Apr-2021, the patient experienced ASTHENIA (felt very weak\weakness). On an unknown date, the patient experienced HYPERSENSITIVITY (severe allergic reaction). On 14-Apr-2021, DIZZINESS (very dizzy), HYPERHIDROSIS (sweated) and VASODILATATION (the vein in her leg felt strange and swollen, under her groin) had resolved. On 30-Apr-2021, ASTHENIA (felt very weak\weakness) had resolved. At the time of the report, HYPERSENSITIVITY (severe allergic reaction) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 14-Apr-2021, Blood pressure measurement: 70/40 decreased. On 29-Apr-2021, Oxygen saturation decreased: 90 oxygen was low, reaching 90.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication information was provided. The patient indicates that she does not take medications. Treatment medications provided by the reporter included apple juice and rest
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Intentional product use issue, Lethargy, Mouth ulceration, Pharyngeal ulceration, Pyrexia
Clinical narrative: She skipped her second dose scheduled 16May2021; mouth ulcers; lethargy; throat ulcers; fever of 101.1; This spontaneous case was reported by a consumer and describes the occurrence of INTENTIONAL PRODUCT USE ISSUE (She skipped her second dose scheduled 16May2021), MOUTH ULCERATION (mouth ulcers), LETHARGY (lethargy), PHARYNGEAL ULCERATION (throat ulcers) and PYREXIA (fever of 101.1) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037B21A) for COVID-19 vaccination.     Concurrent medical conditions included Denture wearer. Concomitant products included ALPRAZOLAM and BUSPIRONE HYDROCHLORIDE (BUSPAR) for Anxiety, TELMISARTAN for Blood pressure, BUPROPION HYDROCHLORIDE (WELLBUTRIN) for Depression, CLINDAMYCIN HYDROCHLORIDE (CLINDAMYCIN) for Infection, HYDROCODONE BITARTRATE, PARACETAMOL (NORCO) and CANNABIS SATIVA (CBD) for Pain, TRAZODONE for Sleep problem, VALACICLOVIR HYDROCHLORIDE (VALTREX) for Viral infection.    On 19-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Apr-2021, the patient experienced MOUTH ULCERATION (mouth ulcers), LETHARGY (lethargy), PHARYNGEAL ULCERATION (throat ulcers) and PYREXIA (fever of 101.1). On an unknown date, the patient experienced INTENTIONAL PRODUCT USE ISSUE (She skipped her second dose scheduled 16May2021). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, INTENTIONAL PRODUCT USE ISSUE (She skipped her second dose scheduled 16May2021), MOUTH ULCERATION (mouth ulcers), LETHARGY (lethargy), PHARYNGEAL ULCERATION (throat ulcers) and PYREXIA (fever of 101.1) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Sex: U
Vaccine: COVID19
Symptoms: Intentional product use issue
Clinical narrative: Patient skipped second dose due to fears from side effects; This spontaneous case was reported by a pharmacist and describes the occurrence of INTENTIONAL PRODUCT USE ISSUE (Patient skipped second dose due to fears from side effects) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 immunisation.     No Medical History information was reported.    On 08-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Mar-2021, the patient experienced INTENTIONAL PRODUCT USE ISSUE (Patient skipped second dose due to fears from side effects). On 17-May-2021, INTENTIONAL PRODUCT USE ISSUE (Patient skipped second dose due to fears from side effects) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant products were reported. No treatment information was provided.  As per client, MI error in DOB capture as 1-JAN-1900
Age: 87.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Myalgia
Clinical narrative: Muscle pain; Shoulder pain; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (Shoulder pain) and MYALGIA (Muscle pain) in an 87-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-May-2021, the patient experienced ARTHRALGIA (Shoulder pain). On an unknown date, the patient experienced MYALGIA (Muscle pain). At the time of the report, ARTHRALGIA (Shoulder pain) and MYALGIA (Muscle pain) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication was reported. No treatment information was reported.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Swelling
Clinical narrative: swelling for two weeks; This spontaneous case was reported by a consumer and describes the occurrence of SWELLING (swelling for two weeks) in a 45-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced SWELLING (swelling for two weeks). At the time of the report, SWELLING (swelling for two weeks) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The patient reported that she was scheduled for the second dose of covid-19 vaccination on 17-May-2021. Concomitant medications were not reported. No treatment medications were reported.
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Urticaria
Clinical narrative: Hives; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (Hives) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026B21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included LISINOPRIL for Blood pressure, ATORVASTATIN for Cholesterol, METFORMIN for Diabetes.    On 02-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Apr-2021, the patient experienced URTICARIA (Hives). At the time of the report, URTICARIA (Hives) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Teatment given included Benadryl and Lisinopril.   This case was linked to MOD-2021-138107 (Patient Link).
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Malaise, SARS-CoV-2 test positive
Clinical narrative: She was sick; COVID-19 Disease Symptoms after First vaccine/ Positive PCR after first vaccine; This spontaneous case was reported by a consumer and describes the occurrence of SARS-COV-2 TEST POSITIVE (COVID-19 Disease Symptoms after First vaccine/ Positive PCR after first vaccine) and MALAISE (She was sick) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-May-2021, the patient experienced SARS-COV-2 TEST POSITIVE (COVID-19 Disease Symptoms after First vaccine/ Positive PCR after first vaccine). On 06-May-2021, the patient experienced MALAISE (She was sick). At the time of the report, SARS-COV-2 TEST POSITIVE (COVID-19 Disease Symptoms after First vaccine/ Positive PCR after first vaccine) and MALAISE (She was sick) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 06-May-2021, COVID-19: positive Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment and concomitant medication information were not provided.   Reporter did not allow further contact
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal discomfort, Headache, Malaise, Vomiting
Clinical narrative: threw up; minor headache; not felt well; Sick to my stomach; This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (not felt well), ABDOMINAL DISCOMFORT (Sick to my stomach), VOMITING (threw up) and HEADACHE (minor headache) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-May-2021, the patient experienced MALAISE (not felt well) and ABDOMINAL DISCOMFORT (Sick to my stomach). On 16-May-2021, the patient experienced HEADACHE (minor headache). On 17-May-2021, the patient experienced VOMITING (threw up). At the time of the report, MALAISE (not felt well), ABDOMINAL DISCOMFORT (Sick to my stomach), VOMITING (threw up) and HEADACHE (minor headache) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported. Treatment information was not provided.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Ringing in ears; This spontaneous case was reported by a consumer and describes the occurrence of TINNITUS (Ringing in ears) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 0034214) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Mar-2021, the patient experienced TINNITUS (Ringing in ears). At the time of the report, TINNITUS (Ringing in ears) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was reported. No treatment medication was reported.   Most recent FOLLOW-UP information incorporated above includes: On 24-Jun-2021: Follow up received which included no new information as reporter  was unable to edit Adverse event reporting form sent in the follow up letter.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Tooth extraction, Tooth infection, Toothache, Vaccination site erythema
Clinical narrative: Tooth extracted; Tooth starting hurting/tooth infection; Area was warm; Area where she got the shot from the bottom and down arm was red; Area where she got the shot from the bottom and down arm was itchy; Tooth starting hurting/tooth infection; Arm was sore; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Arm was sore), TOOTH INFECTION (Tooth starting hurting/tooth infection), TOOTHACHE (Tooth starting hurting/tooth infection), TOOTH EXTRACTION (Tooth extracted) and VACCINATION SITE WARMTH (Area was warm) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022B21A.) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Tooth infection and Allergy. Concomitant products included AZITHROMYCIN for Tooth infection.    On 11-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-May-2021, the patient experienced PAIN IN EXTREMITY (Arm was sore). On 13-May-2021, the patient experienced TOOTHACHE (Tooth starting hurting/tooth infection). On 16-May-2021, the patient experienced VACCINATION SITE ERYTHEMA (Area where she got the shot from the bottom and down arm was red) and VACCINATION SITE PRURITUS (Area where she got the shot from the bottom and down arm was itchy). On 17-May-2021, the patient experienced VACCINATION SITE WARMTH (Area was warm). On an unknown date, the patient experienced TOOTH INFECTION (Tooth starting hurting/tooth infection) and TOOTH EXTRACTION (Tooth extracted). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Adverse event, at an unspecified dose and frequency. On 14-May-2021, PAIN IN EXTREMITY (Arm was sore) had resolved. At the time of the report, TOOTH INFECTION (Tooth starting hurting/tooth infection), TOOTH EXTRACTION (Tooth extracted), VACCINATION SITE WARMTH (Area was warm), VACCINATION SITE ERYTHEMA (Area where she got the shot from the bottom and down arm was red) and VACCINATION SITE PRURITUS (Area where she got the shot from the bottom and down arm was itchy) outcome was unknown and TOOTHACHE (Tooth starting hurting/tooth infection) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment information included Benadryl cream.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pruritus, Vaccination site warmth
Clinical narrative: Tooth extracted; Tooth starting hurting/tooth infection; Area was warm; Area where she got the shot from the bottom and down arm was red; Area where she got the shot from the bottom and down arm was itchy; Tooth starting hurting/tooth infection; Arm was sore; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Arm was sore), TOOTH INFECTION (Tooth starting hurting/tooth infection), TOOTHACHE (Tooth starting hurting/tooth infection), TOOTH EXTRACTION (Tooth extracted) and VACCINATION SITE WARMTH (Area was warm) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022B21A.) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Tooth infection and Allergy. Concomitant products included AZITHROMYCIN for Tooth infection.    On 11-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-May-2021, the patient experienced PAIN IN EXTREMITY (Arm was sore). On 13-May-2021, the patient experienced TOOTHACHE (Tooth starting hurting/tooth infection). On 16-May-2021, the patient experienced VACCINATION SITE ERYTHEMA (Area where she got the shot from the bottom and down arm was red) and VACCINATION SITE PRURITUS (Area where she got the shot from the bottom and down arm was itchy). On 17-May-2021, the patient experienced VACCINATION SITE WARMTH (Area was warm). On an unknown date, the patient experienced TOOTH INFECTION (Tooth starting hurting/tooth infection) and TOOTH EXTRACTION (Tooth extracted). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Adverse event, at an unspecified dose and frequency. On 14-May-2021, PAIN IN EXTREMITY (Arm was sore) had resolved. At the time of the report, TOOTH INFECTION (Tooth starting hurting/tooth infection), TOOTH EXTRACTION (Tooth extracted), VACCINATION SITE WARMTH (Area was warm), VACCINATION SITE ERYTHEMA (Area where she got the shot from the bottom and down arm was red) and VACCINATION SITE PRURITUS (Area where she got the shot from the bottom and down arm was itchy) outcome was unknown and TOOTHACHE (Tooth starting hurting/tooth infection) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment information included Benadryl cream.
Sex: U
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: past the 42 day interval of the first dose; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (past the 42 day interval of the first dose) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 16-May-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (past the 42 day interval of the first dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (past the 42 day interval of the first dose) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was reported. no treatment medication was provided   Most recent FOLLOW-UP information incorporated above includes: On 16-Jul-2021: Follow up received on 16 Jul 2021 contains no significant information
Sex: F
Vaccine: COVID19
Symptoms: Eye pruritus, Papule, Skin discolouration
Clinical narrative: eye has been itching a lot; tiny bump around her eye; Now her skin changed to very dark, like black; This spontaneous case was reported by a pharmacist and describes the occurrence of EYE PRURITUS (eye has been itching a lot), PAPULE (tiny bump around her eye) and SKIN DISCOLOURATION (Now her skin changed to very dark, like black) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Atopy.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced EYE PRURITUS (eye has been itching a lot), PAPULE (tiny bump around her eye) and SKIN DISCOLOURATION (Now her skin changed to very dark, like black). At the time of the report, EYE PRURITUS (eye has been itching a lot), PAPULE (tiny bump around her eye) and SKIN DISCOLOURATION (Now her skin changed to very dark, like black) outcome was unknown.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter. No treatment information was provided.    Most recent FOLLOW-UP information incorporated above includes: On 17-Jun-2021: Follow-up document attached - Medical History reported
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Product dose omission issue, Weight decreased
Clinical narrative: First dose on 21Jan2021; second dose not yet received; hHs lost 30 pounds since having the first dose; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (First dose on 21Jan2021; second dose not yet received) and WEIGHT DECREASED (hHs lost 30 pounds since having the first dose) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (First dose on 21Jan2021; second dose not yet received) and WEIGHT DECREASED (hHs lost 30 pounds since having the first dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (First dose on 21Jan2021; second dose not yet received) had resolved and WEIGHT DECREASED (hHs lost 30 pounds since having the first dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided.   This case was linked to US-MODERNATX, INC.-MOD-2021-138800 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-138800:Same reporter (wife case)
Sex: U
Vaccine: COVID19
Symptoms: Accidental underdose
Clinical narrative: 0.1 mL given to unknown batch of patients; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a pharmacist and describes the occurrence of ACCIDENTAL UNDERDOSE (0.1 mL given to unknown batch of patients) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .1 ml. On an unknown date, the patient experienced ACCIDENTAL UNDERDOSE (0.1 mL given to unknown batch of patients). At the time of the report, ACCIDENTAL UNDERDOSE (0.1 mL given to unknown batch of patients) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications reported by investigator  No treatment medications provided by the reporter  They were using 0.1mL instead of the recommended 0.5 mL and did not realize it until after it was given when they took inventory of their doses and realize they had more than expected. All the patients are from today but as of right now they were unsure exactly which patients were effected and believe it was 11 patients   Most recent FOLLOW-UP information incorporated above includes: On 16-Jul-2021: Follow up received on 16-JUL-2021. No new information has been updated in the case.
Age: 48.0
Sex: U
Vaccine: COVID19
Symptoms: Abdominal discomfort, Back pain, Fatigue, Illness, Pyrexia
Clinical narrative: I got sick last week; pain on the insides felt like insides were tearing and felt like back or kidney pain; pain on the insides felt like insides were tearing and felt like back or kidney pain; I had a temperature; fatigue,exhaustion; got sick with my stomach on 5/16; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (I got sick last week), BACK PAIN (pain on the insides felt like insides were tearing and felt like back or kidney pain), RENAL PAIN (pain on the insides felt like insides were tearing and felt like back or kidney pain), ABDOMINAL DISCOMFORT (got sick with my stomach on 5/16) and PYREXIA (I had a temperature) in a 48-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included RIVAROXABAN (XARELTO) and FAMOTIDINE (PEPCID AC) for an unknown indication.   On 12-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-May-2021, the patient experienced ABDOMINAL DISCOMFORT (got sick with my stomach on 5/16). On an unknown date, the patient experienced ILLNESS (I got sick last week), BACK PAIN (pain on the insides felt like insides were tearing and felt like back or kidney pain), RENAL PAIN (pain on the insides felt like insides were tearing and felt like back or kidney pain), PYREXIA (I had a temperature) and FATIGUE (fatigue,exhaustion). At the time of the report, ILLNESS (I got sick last week), BACK PAIN (pain on the insides felt like insides were tearing and felt like back or kidney pain), RENAL PAIN (pain on the insides felt like insides were tearing and felt like back or kidney pain), PYREXIA (I had a temperature) and FATIGUE (fatigue,exhaustion) had resolved and ABDOMINAL DISCOMFORT (got sick with my stomach on 5/16) outcome was unknown.